U.S. FDA says India-made eye drop linked to some infections, blindness and one death

Global Pharma Healthcare did not immediately respond to a Reuters request seeking comment on the FDA statement. "Associated adverse events include hospitalization, one death with bloodstream infection, and permanent vision loss from eye infections," the FDA said. Global Pharma Healthcare did not immediately respond to a Reuters request seeking comment on the FDA statement. It said that as of Jan. 31, the CDC had identified 55 patients in 12 states with infections linked to the use of Artificial Tears distributed by EzriCare, it said. "Associated adverse events include hospitalization, one death with bloodstream infection, and permanent vision loss from eye infections," the FDA said.